The B10.Q congenic strain was originally developed for use in transplantation studies. More recently it has been discovered that there are important immunological differences between the JAX sub-line, B10.D1-H2q/SgJ and the NIAID sub-line B10.D1/-H2q/SgAi. Since their separation, the B10.D1-H2q/SgJ line has acquired a genetic defect which altered its immune phenotype. While B10.D1-H2q/SgJ has been shown to be resistant to the induction of autoimmune arthritis, the NIAID subline has remained susceptible.
The B10.Q congenic was made at the Jackson Laboratory by Dr. Jack Stimpfling . When Stimpfling relocated to Montana he took a colony of the B10.Q line with him, and in 1975, this subline was acquired by Dr. Ron Schwartz at NIAID.
Availability: This model is no longer available.
Shaw M, Boyartchuk V, Wong S, Karaghiosoff M, Ragimbeau J, Pellegrini S, Muller M, Dietrich W and Yap G. A natural mutation in the Tyk2 pseudokinase domain underlies altered susceptibility of B10.Q/J mice to infection and autoimmunity. PNAS 2003 100: 11594-11599